#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Exudative retinopathy MELAS syndrome Squamous cell carcinoma of the cervix Squamous cell carcinoma of the vulva Congenital nephrogenic diabetes insipidus Congenital myopathy Partial lipodystrophy T-cell lymphoma Hyperchylomicronaemia Alveolar proteinosis Acute leukaemia Adult T-cell lymphoma/leukaemia refractory Autoimmune myositis Primary adrenal insufficiency Thalassaemia beta More trials…

    Learn about Rare Diseases

    Mucopolysaccharidosis III – Diagnostics Ewing’s sarcoma recurrent – Treatment Pemphigoid – Life with Disease Gaucher’s disease type III – Life with Disease Undifferentiated sarcoma – Trials in Disease Synovial sarcoma – Treatment Acute respiratory distress syndrome – Diagnostics Cytokine release syndrome – Life with Disease Mucopolysaccharidosis I – Treatment Progressive supranuclear palsy – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Msv-Allo Hyoscine Butylbromide INSULIN DETEMIR Cendakimab 10-1074-Ls Gentamicin Sulfate Paliperidone Eo2317 Riboflavin Bp Larotrectinib Sulfate Blinatumomab Tub-040 HYDROGEN PEROXIDE Inclisiran Levofloxacin Hemihydrate Staphylococcus Aureus Teprotumumab Valoctocogene Roxaparvovec Tas3351 Acetylcysteine More therapies…

    Learn about Your Condition

    Piriformis syndrome Lymphangioleiomyomatosis Fibromyalgia Rheumatic disorder Thermal burn Cardiogenic shock Osteosarcoma recurrent Anal cancer recurrent Chondrosarcoma metastatic Left ventricular failure Sinusitis bacterial Craniopharyngioma Immune thrombocytopenia Foot deformity Diabetic foot infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study on Crizotinib for Treating Severe Neurofibromatosis Type 2 in Children Not Eligible for Surgery or Radiotherapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neurofibromatosis
    Investigated Drugs:
    • Crizotinib
    Poland

  • Study of Risedronate Sodium for Patients with Dilated Cardiomyopathy Due to Troponin T Gene Mutation

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Dilated cardiomyopathy
    Investigated Drugs:
    • Risedronate Sodium
    Spain

  • Study of Gilteritinib, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Not Eligible for Intensive Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Gilteritinib
    • Azacitidine
    • Venetoclax
    Germany

  • Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Erdheim-Chester disease
    • Langerhans cell sarcoma
    • Rosai-Dorfman syndrome
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    Poland

  • Study on the Effectiveness of Pembrolizumab and Ipilimumab in Melanoma Patients with Brain Metastases Requiring Steroid Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Binimetinib
    • Dabrafenib
    • Encorafenib
    Denmark

  • Study of Tislelizumab immunotherapy in patients with liver cancer (hepatocellular carcinoma) who have moderately impaired liver function (Child-Pugh B)

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Tislelizumab
    France
Previous Page
1 … 350 351 352 353 354 … 1,651
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!